Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

MEGAbIT: The role of magnetoencephalography in assessment and diagnosis in mild traumatic brain injury
Neurocritical Care
ES2 - Emerging Science 2 (6:12 PM-6:18 PM)
008

MEGAbIT, an MRC funded study (Clinical Trials reference: NCT03867513), combined magnetoencephalography (MEG) with ultrahigh-field MRI, to detect functional and structural neuroimaging abnormalities within two weeks of mTBI.

Can measuring brain wave activity differentiate those with mild traumatic brain injury (mTBI) from orthopaedic trauma controls (with no head injury), and healthy controls.

We recruited 41 participants within two weeks of an emergency department visit and assessed resting state and task specific MEG, followed by ultrahigh-field MRI including structural, susceptibility, and diffusion sequences. Participant reported symptom scales were completed at baseline, three, and six months. Two prospectively selected analyses of resting state MEG data were conducted: excess delta band activity, the most commonly reported MEG abnormality in the literature, and reduced beta band burst coincidence connectivity, as this has previously demonstrated abnormalities in sub-acute mTBI.

No significant difference was found in global mean delta power between the mTBI cohort and either control cohort. However, a reduction in beta band burst coincidence connectivity was observed in the mTBI cohort compared to the healthy control cohort (Z=-2.612, p = 0.009). This gave a sensitivity of 86% and a modest specificity of 51%. Half our mTBI cohort had persistent self-reported disability, consistent with large prospective registry studies. Susceptibility weighted imaging revealed only two mTBI participants with microhaemorrhages, their clinical course did not differentiate them from others in the mTBI cohort.

Given the global prevalence of mTBI and the high levels of persistent disability it causes, there is an urgent need for neuroimaging tools that link to both the underlying neuropathology and reported symptoms. Our results suggest that mTBI impairs the dynamic coordination of neural network activity. This finding was more sensitive than structural ultrahigh-field MRI and requires further exploration.

Authors/Disclosures
Christopher Martin Allen, MBBS
PRESENTER
The institution of Dr. Allen has received research support from National Institute for Health and Care Research (Research for Patient Benefit) [grant number PB-PG-0418-20044].
Lukas Rier, PhD Dr. Rier has nothing to disclose.
Lauren Elizabeth Gascoyne, PhD (University of Nottingham) Dr. Gascoyne has nothing to disclose.
Rob Dineen The institution of Rob Dineen, 8063 has received research support from UK National Institute of Health Research.
Roshan Das Nair (University of Nottingham) Roshan Das Nair has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. The institution of Roshan Das Nair has received research support from MS Society. The institution of Roshan Das Nair has received research support from NIHR. The institution of Roshan Das Nair has received research support from MRC. The institution of Roshan Das Nair has received research support from Stroke Association. Roshan Das Nair has received publishing royalties from a publication relating to health care. Roshan Das Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Chair of RfPB RAC East Midlands with NIHR.
Matthew Jon Brookes, PhD (University of Nottingham) No disclosure on file
Nikolaos Evangelou, PhD (Nottingham University, QMC campus) Dr. Evangelou has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis . Dr. Evangelou has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis . The institution of Dr. Evangelou has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Roche. Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck . Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen . Dr. Evangelou has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for biogen. Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for UK crown prosecution service. Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Novartis .